| abstract |
The present disclosure relates to compounds that are sodium channel inhibitors and their use in the treatment of various pathological conditions, including cardiovascular disease and diabetes. In certain embodiments, the structure of the compound is represented by formula (I), wherein n, R 1 , R 2 , R 2 ′ , R 3 , R 4 , R 5 , R 6 and R 7 are Methods for the preparation and use of compounds as described herein and pharmaceutical compositions containing them. Disease states addressed by the present invention include, for example, atrial arrhythmia (eg, atrial fibrillation), ventricular arrhythmia (eg, ventricular tachycardia or ventricular fibrillation), heart failure (eg, congestive heart failure, diastolic heart failure, Systolic heart failure or acute heart failure). |